Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

International Nursing Organizations II01:28

International Nursing Organizations II

1.1K
The World Health Organization (WHO) is a specialized agency of the United Nations based in Geneva. The WHO has many initiatives that center around health. Primarily, they lead global efforts to expand universal health coverage using science-based policies and programs. They are also responsible for shaping health research agendas and developing norms and standards.
The WHO provides expert team support, including funding, vaccines, testing, and treatment tools at the country level to fight...
1.1K
Primary Healthcare Services01:30

Primary Healthcare Services

1.6K
Primary care promotes wellness and prevents disease. This care includes health promotion, education, protection (such as immunizations), early disease screening, and environmental considerations. Settings providing this type of healthcare include physician offices, public health clinics, school nursing, and community health nursing.
In 1978, international leaders convened in Alma-Ata, Kazakhstan, for what would be a pivotal event in global health. The Alma-Ata Declaration was the first to call...
1.6K
Methods Of Healthcare Delivery System01:26

Methods Of Healthcare Delivery System

3.6K
At the different levels of the healthcare system, we see varying methods of healthcare used. These methods include managed care systems, case management, and primary healthcare.
Managed Care System:
The managed care system is designed to control the cost while maintaining the quality of care. The patient's care from admission to discharge is planned by the primary care provider or the case manager, also known as the gatekeeper. In a managed care system, the number of care providers is...
3.6K
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

3.1K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.1K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

7.8K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.8K
Enhanced Elimination of Poison01:26

Enhanced Elimination of Poison

602
Poison can be effectively removed from the gastrointestinal (GI) tract through various decontamination procedures.
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
602

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emergence of Reassortant Crimean-Congo Hemorrhagic fever virus lineages, Pakistan, 2023-2024.

Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases·2026
Same author

Lung Microbiome Diversity, Infection Dynamics, and Microbe-Mediated Cross-Protection.

MicrobiologyOpen·2026
Same author

Gut dysbiosis and microbial metabolites in atopic dermatitis: implications for immune regulation along gut-skin axis.

Frontiers in microbiology·2026
Same author

Therapeutic modulation of HIV-1 using miRNAs and lncRNAs: from bench to bedside.

Virology journal·2026
Same author

Discovery of potential antiviral compounds and accelerating the therapeutic discovery against monkeypox virus.

Scientific reports·2026
Same author

Eggerthella lenta: A rare cause of septic shock and sepsis after Fournier's gangrene.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2025

Related Experiment Video

Updated: Oct 5, 2025

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.9K

Progress on global hepatitis elimination targets.

Yasir Waheed1

  • 1Multidisciplinary Laboratory, Foundation University Medical College, Foundation University Islamabad, Islamabad 44000, Pakistan. yasir_waheed_199@hotmail.com.

World Journal of Gastroenterology
|January 24, 2022
PubMed
Summary

Global hepatitis elimination efforts face significant challenges. Despite progress in treatment, viral hepatitis B (HBV) and C (HCV) targets remain unmet due to funding gaps and the COVID-19 pandemic, necessitating urgent action.

Keywords:
Blood donationsHarm reductionHepatitis B vaccinationHepatitis eliminationSafe injections

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.0K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.5K

Related Experiment Videos

Last Updated: Oct 5, 2025

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.9K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.0K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.5K

Area of Science:

  • Public Health
  • Infectious Diseases
  • Global Health Strategies

Background:

  • The World Health Assembly adopted a Global Health Sector Strategy in 2016 aiming for viral hepatitis elimination by 2030.
  • Key targets include a 90% reduction in hepatitis B virus (HBV) and hepatitis C virus (HCV) incidence and a 65% reduction in mortality.
  • Progress has been made, but current trajectories indicate these targets will not be met without accelerated efforts.

Purpose of the Study:

  • To assess the progress towards global hepatitis elimination targets set for 2020 and 2030.
  • To highlight the challenges hindering the achievement of these targets.
  • To emphasize the urgent need for intensified global action against viral hepatitis.

Main Methods:

  • Analysis of global data on viral hepatitis incidence and mortality.
  • Review of progress in HCV treatment uptake.
  • Assessment of the impact of external factors like the COVID-19 pandemic and funding on elimination strategies.

Main Results:

  • HCV treatment reached 9.4 million people in the last 5 years, a significant increase but short of the 40 million target by 2030.
  • Annual deaths from HBV and HCV decreased from 1.4 million to 1.1 million, falling short of the <0.5 million target for 2030.
  • The COVID-19 pandemic and lack of major donor investment have severely impacted hepatitis control efforts.

Conclusions:

  • Current progress is insufficient to meet the 2030 hepatitis elimination goals.
  • Accelerated and intensified efforts are crucial to bridge the gap.
  • Urgent need for increased investment and sustained global commitment to combat viral hepatitis.